Acetylcholine Chloride

PreclinicalSmall molecule

SSemmelweis University

Acetylcholine Chloride is one of 3 small molecule programs targeting Vasodilation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VasodilationActive, not recruiting

VasodilationPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Vasodilation

#DrugCompanyPhaseTrials

Miochol

BBausch Health Americas, Inc.

Phase 1

3 2

Nipride

EExela Pharma Sciences, LLC.

Preclinical

1 3

Acetylcholine Chloride

SSemmelweis University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vasodilation1 trial

Investigation of Endothelium-dependent Vasodilation in Human Gingiva

Active, not recruiting·SSemmelweis University·N/A·NCT06454084·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Acetylcholine Chloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acetylcholine Chloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acetylcholine Chloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Semmelweis University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSemmelweis University

Acetylcholine Chloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vasodilation1 trial

References

Drug Info

Quick Facts

Related News